Ontruzant (Trastuzumab)

Trastuzumab binds to the extracellular domain of the HER2 receptor, blocking its activation and downstream signalling pathways that drive tumour growth. It also flags HER2‑overexpressing cells for destruction by immune cells through antibody‑dependent cellular cytotoxicity.

The dosing regimen for Ontruzant is determined by the treating oncologist based on the specific indication, patient weight, and clinical response. Prescribers follow established guidelines and adjust the infusion schedule as needed.

Ontruzant is not recommended for use during pregnancy because it may cause fetal harm. Women of child‑bearing potential should use effective contraception. Breastfeeding is also discouraged, as trastuzumab can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the Ontruzant product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Ontruzant (trastuzumab) is a well‑established HER2‑directed monoclonal antibody with a long safety record. Compared with newer agents such as pertuzumab or trastuzumab‑deruxtecan, it has a similar mechanism but may differ in efficacy, toxicity profile, and approved combination regimens. Choice of therapy depends on disease stage, prior treatments, and physician judgment.

Ontruzant must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. If temperature excursions occur, the product should be inspected for visual changes before use.

Ontruzant is given as an intravenous infusion under the supervision of qualified healthcare professionals. The infusion rate and duration are determined by the prescribing physician and may be adjusted based on patient tolerance and clinical response.

The most serious risks include cardiac dysfunction or heart failure, severe infusion‑related reactions such as anaphylaxis, and rare pulmonary toxicity. Patients are monitored regularly for cardiac function and signs of hypersensitivity throughout treatment.

Ontruzant should not be used in patients with known hypersensitivity to trastuzumab or any of its excipients, and it is contraindicated in individuals with uncontrolled cardiac disease or recent significant declines in left ventricular ejection fraction. Clinicians must assess each patient’s medical history before initiating therapy.